Callisto Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Callisto Pharmaceuticals

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	12/3/2005 12:14:46 PM
	of 19

2000 - Atiprimod (AnorMED). Lakings DB. Drug Safety Evaluation Consulting Inc, 441 Green Glade Road, Birmingham, AL 35244, USA. Dblakings@aol.com Atiprimod is a macrophage-targeting oral cytokine inhibitor which is being developed by AnorMED as a potential treatment for rheumatoid arthritis and other autoimmune diseases. Phase I trials have been successfully completed and phase II multicenter trials have been approved by the FDA [303260]. The compound was discovered in a joint research and development program with SmithKline and French (now SmithKline Beecham, SB) but following acceptance of the phase II protocol by the FDA, SB decided not to proceed with further development of atiprimod as a result of an internal restructuring program [350042]. All rights to atiprimod and other azaspiranes developed in this program have reverted to AnorMED, which is seeking corporate partners for further development of the compound [303260,337657]. The compound was originally disclosed in European patent, EP-00310321, entitled 'Preparation of N-aminoalkyl-2-azaspiro[4.5]decanes and analogs as immunosuppresants', while a cost-effective, efficacious pilot plant synthesis has also been described [298722]. PMID: 16103943 [PubMed] ncbi.nlm.nih.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next